



Not for release to US wire services or distribution in the United States

8 December 2022

## Extension of March Options Offer under Prospectus

**Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** refers to the offers ("Offers") under the prospectus lodged to ASIC and ASX on 28 November 2022 ("Prospectus").

The Company advises that the indicative timetable in the Prospectus has been revised and is set out below.

Event	Date
Lodgement of Prospectus with ASIC and the ASX	28 November 2022
Opening Date of the Offers	29 November 2022
Closing Date of the Obsidian Options Offer	2 December 2022
Issue of the Obsidian Options and lodgement of Appendix 2A with ASX	2 December 2022
Closing Date of the March Options Offer	9 December 2022 at 5:30pm WST
Issue of the March Options and Lodgement of Appendix 3G with ASX	12 December 2022
Closing Date of Convertible Notes Offer	2 December 2022
Issue of Convertible Notes Offer and Lodgement of Appendix 3G	2 December 2022
Closing Date of the Cleansing Offer	8 December 2022
Quotation of Obsidian Options	6 December 2022

Shareholders are cautioned that the above timetable is indicative only and is subject to change for reasons both inside and outside of the Company's control. The Company reserves the right to vary the timetable in its discretion, without warning, subject to ASX Listing Rules.

Full details of the Offers are set out in the Prospectus.

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and were not offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

**-Ends-**



### **Authority and Contact Details**

This announcement has been authorised for release by William Lay, CEO and Managing Director.

For further information, please contact:

### **Investor Enquiries**

Creso Pharma Limited  
E: [info@cresopharma.com](mailto:info@cresopharma.com)  
P: +61 (0) 497 571 532

### **About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

### **Creso Pharma offices:**

#### **Australia**

Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

#### **Switzerland**

Allmendstrasse 11, 6310 Steinhausen, Schweiz

#### **Canada**

59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0